Cargando…

Identifying men affected by changes in PSA screening in the COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	Bass, E.J., Bertonelli Tanaka, M., Connor, M.J., Walters, U., Eldred-Evans, D., Sarkar, P., Hosking-Jervis, F., Bhola-Stewart, H., Pegers, E., Powell, L., Leelamany, D., Wong, K., Ahmad, S., Tam, H., Gordon, S., Hrouda, D., Mccracken, S., Winkler, M., Ahmed, H.U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association of Urology. Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155264/ http://dx.doi.org/10.1016/S0302-2838(22)00455-9

Ejemplares similares

Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study
por: Eldred-Evans, David, et al.
Publicado: (2023)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection
por: Pchejetski, Dmitri, et al.
Publicado: (2023)

Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study
por: Eldred-Evans, David, et al.
Publicado: (2021)

Safety and adverse events of urgent elective surgery during COVID-19 within three UK hospitals
por: Bertoncelli Tanaka, M, et al.
Publicado: (2020)

Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning
por: Eldred-Evans, David, et al.
Publicado: (2020)

PsaF Is a Membrane-Localized pH Sensor That Regulates psaA Expression in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2021)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual
por: Wever, E M, et al.
Publicado: (2012)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels
por: Jesser, C, et al.
Publicado: (2008)

Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis
por: Bass, E. J., et al.
Publicado: (2021)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study
por: Bass, E.J., et al.
Publicado: (2021)

Rheological and Mechanical Properties of an Acrylic PSA
por: Simões, Beatriz D., et al.
Publicado: (2023)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Cost implications of PSA screening differ by age
por: Rao, Karthik, et al.
Publicado: (2018)

Utility of Free/Total Prostate Specific Antigen (f/t PSA) Ratio in Diagnosis of Prostate Carcinoma
por: Thakur, V., et al.
Publicado: (2004)

Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8(+) T cells in the mouse
por: Lemke, Caitlin D., et al.
Publicado: (2011)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening
por: Koo, Kevin, et al.
Publicado: (2017)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Prostate imaging features that indicate benign or malignant pathology on biopsy
por: Lovegrove, Catherine Elizabeth, et al.
Publicado: (2018)

Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
por: Pye, Hayley, et al.
Publicado: (2021)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
por: Doherty, A P, et al.
Publicado: (2000)

Feasibility of familial PSA screening: psychosocial issues and screening adherence
por: Sweetman, J, et al.
Publicado: (2006)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b0p9lna91rci9qh5b207v25ovu